Evaxion Reports P-I/IIa Results of EVX-02 for the Treatment of Resected Melanoma
Shots:
- The company reported results from the P-I/IIa study evaluating EVX-02 in combination with a checkpoint inhibitor and targeting cancer mutations neoantigens in patients with resected melanoma. The results from the P-I study are expected in Q2’23
- The interim safety and immunogenicity data from the first eight patients showed that EVX-02 induced CD4+ and CD8+ specific T-cell responses in all patients & provides proof of mechanism for DNA-delivery technology & EVX-02-DNA offers immune reactions to its encoded neoantigen peptides
- The therapy was well tolerated & mild AEs observed, T-cell responses were robust and long-lasting
Ref: Globenewswire | Image: Evaxion
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
